Since we have shown here that the cytokine-induced pathway for IFN-γ production is blocked by rapamycin, mTOR may be a therapeutic target in the treatment of autoimmune diseases characterized by IFN-γ overexpression. The gene discussed is IFNG; the disease is autoimmune disease.